首页 | 本学科首页   官方微博 | 高级检索  
检索        


Number crunching in the cancer stem cell market
Authors:Malcolm R Alison  Shahriar Islam  Susan ML Lim
Institution:(1) Centre for Diabetes and Metabolic Medicine, ICMS, Barts and The London School of Medicine and Dentistry, 4 Newark Street, E1 2AT London, UK;(2) Department of Orthopaedic Surgery, National, University of Singapore, 5 Lower Kent Ridge Road, 119074 Singapore, Singapore
Abstract:Like their normal counterparts, many tumours are thought to have a hierarchical organization, albeit a disorganized one. Accordingly, the concept of cancer stem cells has emerged, and that these cells are responsible for perpetuating tumour existence. Operationally, cancer stem cells are regarded as prospectively purified cells that are the most effective at tumour initiation in an in vivo assay, usually after xenotransplantation to NOD/SCID mice. The conventional wisdom is that such tumour-initiating cells are rare based upon having to xenotransplant large numbers of human tumour cells into immunodeficient mice to propagate the tumour, but new evidence indicates that perhaps these cells are not so rare, at least in malignant melanoma, if a supportive soil is provided for the transplanted cells along with further restriction of the murine host's immune response.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号